What Is Palopegteriparatide? Definition and What Research Reports

Definition

Palopegteriparatide is a long-acting prodrug of teriparatide, the synthetic 1-34 amino-acid fragment of human parathyroid hormone (PTH). In the prodrug, the teriparatide peptide is bound to an inert carrier molecule by a linker that cleaves slowly under physiological conditions, so a single daily subcutaneous injection releases free PTH(1-34) continuously rather than as a short pulse. The literature describes it as a PTH replacement therapy (sometimes called "PTH substitution therapy") for adults with chronic hypoparathyroidism — a condition in which the parathyroid glands do not produce enough hormone, most often after neck surgery. It is not a nutritional supplement, a research-use-only chemical, or a compounded product; reviews describe it as a regulated pharmaceutical developed for a rare endocrine disease, and one commentary described its regulatory approval in the United States as an orphan drug for chronic hypoparathyroidism (PMID 41675830). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment.

Class of Molecule and Where It Comes From

Palopegteriparatide belongs to the peptide-hormone analogue class. Its active moiety is identical in sequence to the biologically active N-terminal portion of endogenous human parathyroid hormone, PTH(1-34), which binds the PTH1 receptor in bone and kidney. The distinguishing feature is not the peptide but the delivery chemistry: a carrier-linker conjugate (a "TransCon" style prodrug design) that holds the peptide inactive until the linker hydrolyses.

• Parent peptide: teriparatide, PTH(1-34), a 34-amino-acid fragment of human parathyroid hormone.
• Modification: covalent attachment to an inert carrier via a cleavable linker, producing a prodrug with sustained release of the unmodified peptide.
• Route described in trials: once-daily subcutaneous injection.
• Contrast in the literature: reviews discuss it alongside recombinant full-length PTH(1-84) as the two PTH substitution approaches studied in chronic hypoparathyroidism (PMID 39987371).

How the Term Is Used in Peptide Research

In the published literature the word appears almost exclusively in an endocrinology context. Typical usages include:

• As a trial intervention name — the phase 2 paTH Forward and phase 3 PaTHway trials are named in reports describing palopegteriparatide in adults with chronic hypoparathyroidism (PMID 38691316).
• As a drug-class exemplar — reviews of PTH substitution therapy use it to illustrate how prodrug chemistry changes the pharmacokinetic profile of a peptide hormone relative to short-acting teriparatide (PMID 39987371).
• As a mechanistic probe — one review examined how PTH replacement with palopegteriparatide relates to synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism (PMID 42605157).
• As a health-economics and real-world term — a multicriteria decision analysis assessed its value contribution in adults with chronic hypoparathyroidism (PMID 41134515), and a separate report described early United States real-world treatment patterns and outcomes (PMID 40846304).

Because it is a prescription medicine studied in registered clinical trials, the term is not generally used to describe material sold for laboratory or personal experimentation, unlike many peptides catalogued in glossaries of this kind.

What the Published Literature Reports

The studies below are summarised only to describe what researchers measured and reported. Nothing here is a protocol, and no dosing schedule is described.

Kidney outcomes

A report of 1-year results from the phase 3 PaTHway trial stated that palopegteriparatide treatment improved renal function in adults with chronic hypoparathyroidism (PMID 38691316). A later analysis of the same phase 3 programme reported sustained improvement in renal function at 2 years in adults with chronic hypoparathyroidism (PMID 42166177). Renal endpoints are prominent in this literature because conventional management of hypoparathyroidism with calcium and active vitamin D has long been associated with kidney complications.

Skeletal and biochemical outcomes

A report of skeletal dynamics through 3 years of the phase 2 paTH Forward trial described bone outcomes in adults with chronic hypoparathyroidism treated with palopegteriparatide (PMID 41636590). Separately, a review discussed the relationship between PTH replacement with palopegteriparatide and the synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism, the pathway through which PTH normally supports intestinal calcium absorption (PMID 42605157).

Symptoms and patient-reported outcomes

An extension analysis of the paTH Forward trial reported patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism (PMID 41365829). Patient-reported endpoints matter in this disease because symptoms such as fatigue, cognitive complaints and paraesthesia are not fully captured by serum calcium alone.

Other populations studied

A phase 3 trial reported 52-week results in Japanese adults with hypoparathyroidism (PMID 41260697), and a case report described palopegteriparatide as a therapeutic option in pediatric autosomal dominant hypocalcemia type 1 (PMID 42388864). A single case report is the weakest form of clinical evidence and describes one individual rather than a population effect.

Discontinuation and Safety Observations: What Studies Report

The published record includes observations about what happened when treatment stopped. A 2025 report described a rebound effect following the discontinuation of palopegteriparatide (PMID 40956444). Beyond that, an early real-world report of United States treatment patterns and outcomes described how patients with hypoparathyroidism were managed in routine practice rather than under trial conditions (PMID 40846304). Reviews of PTH substitution therapy discuss monitoring considerations for both PTH(1-84) and palopegteriparatide in chronic hypoparathyroidism (PMID 39987371). Detailed adverse-event tables are held in the primary publications and their regulatory labelling; this glossary entry does not reproduce them, and no individual should interpret any of the above as an indication of suitability.

Quick Reference Table

Common Points of Confusion

• Palopegteriparatide vs. teriparatide: teriparatide is the active PTH(1-34) peptide itself; palopegteriparatide is a carrier-linked prodrug designed to release that same peptide slowly.
• Palopegteriparatide vs. PTH(1-84): reviews treat these as two distinct PTH substitution strategies for chronic hypoparathyroidism, differing in peptide length and pharmacokinetics (PMID 39987371).
• Hypoparathyroidism vs. osteoporosis indications: the palopegteriparatide literature summarised here concerns chronic hypoparathyroidism, not osteoporosis treatment.

This entry is definitional. It does not describe dosing, scheduling, monitoring or suitability for any person, and it should not be used to make decisions about treatment. Researchers continue to publish extension and real-world data, so the evidence base described above is a snapshot rather than a final account.

References

• Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial (Advances in Therapy, 2024)
• Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Rebound Effect Following the Discontinuation of Palopegteriparatide (Calcified Tissue International, 2025)
• Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism (Endocrine Practice, 2025)
• Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA) (Advances in Therapy, 2025)
• PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1-84 and Palopegteriparatide (Current Osteoporosis Reports, 2025)
• Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward Trial (Journal of Bone and Mineral Research, 2026)
• Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial (Journal of Bone and Mineral Research, 2026)
• Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug (Annals of Medicine and Surgery, 2026)
• Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial (Endocrine Journal, 2026)
• Case Report: Palopegteriparatide as a novel therapeutic option in pediatric autosomal dominant hypocalcemia type 1 (Frontiers in Endocrinology, 2026)
• The impact of parathyroid hormone replacement with palopegteriparatide on synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism (Expert Review of Clinical Pharmacology, 2026)